Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong market demand in the peptide sector [1] Financial Performance - The expected revenue for 泰德医药 is projected to be between RMB 5.55 billion and RMB 5.85 billion, representing a year-on-year increase of approximately 25.5% to 32.3% [1] - The anticipated profit is estimated to be between RMB 2 billion and RMB 2.3 billion, indicating a substantial year-on-year increase of approximately 237.8% to 288.5% [1] Strategic Factors - Revenue growth is attributed to the successful execution of the "follow-on molecule" strategy and the advantages of the integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform [1] - The company highlights its industry-leading project delivery timeliness and excellent project execution track record as key contributors to its performance [1] - There is a strong and growing demand from key clients for the company's services, driven by advancements in its research and development pipeline and the rapid expansion of the global peptide market, particularly in the GLP-1 sector [1]

Core Viewpoint - The company, 泰德医药 (Tide Pharmaceutical), anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong demand in the global peptide market [1] Financial Projections - The projected revenue for the fiscal year ending December 31, 2025, is approximately RMB 5.55 billion to RMB 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of RMB 4.42 billion for the fiscal year ending December 31, 2024 [1] - The expected profit for the fiscal year ending December 31, 2025, is around RMB 2 billion to RMB 2.3 billion, which marks an increase of approximately 237.8% to 288.5% from the estimated profit of RMB 592 million for the fiscal year ending December 31, 2024 [1] - The adjusted net profit (non-IFRS measure) for the fiscal year ending December 31, 2025, is projected to be about RMB 2 billion to RMB 2.3 billion, reflecting an increase of approximately 16.3% to 33.7% compared to the adjusted net profit of RMB 1.72 billion for the fiscal year ending December 31, 2024 [1] Growth Drivers - Revenue growth is primarily attributed to the successful implementation of the "follow-on molecule" strategy, the advantages of the company's integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform, and the strong demand from key clients due to advancements in their R&D pipelines [1] - The rapid expansion of the global peptide market, particularly in the glucagon-like peptide-1 (GLP-1) sector, is also a significant factor contributing to the anticipated growth [1]

Core Viewpoint - The company, 泰德医药 (Tide Pharmaceutical), anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong demand in the global peptide market, particularly in the GLP-1 sector [1][2] Group 1: Revenue Projections - The company expects revenue for the fiscal year ending December 31, 2025, to be approximately RMB 5.55 billion to 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of RMB 4.42 billion for the fiscal year ending December 31, 2024 [1] - The revenue growth is attributed to the successful implementation of the "follow-on molecule" strategy and the advantages of the integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform [1] Group 2: Profit Projections - The company projects profit for the fiscal year ending December 31, 2025, to be around RMB 2 billion to 2.3 billion, which marks an increase of approximately 237.8% to 288.5% compared to the estimated profit of RMB 59.2 million for the fiscal year ending December 31, 2024 [1] - The adjusted net profit (non-IFRS measure) is expected to be about RMB 2 billion to 2.3 billion, reflecting an increase of approximately 16.3% to 33.7% from the adjusted net profit of RMB 1.72 billion for the fiscal year ending December 31, 2024 [1] Group 3: Factors Influencing Profit Growth - Profit growth is primarily driven by the aforementioned revenue increase, operational management optimization leading to cost savings and efficiency improvements, and fair value gains on financial liabilities recognized for the fiscal year ending December 31, 2025 [2] - The adjusted net profit increase is also attributed to revenue growth and operational efficiency enhancements [2]

Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong demand in the global peptide market, particularly in the GLP-1 sector [1][2]. Revenue Projections - The company expects revenue for the fiscal year ending December 31, 2025, to be approximately RMB 5.55 billion to 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of approximately RMB 4.42 billion for the fiscal year ending December 31, 2024 [1]. - The revenue growth is attributed to the successful implementation of the "follow-on" strategy and the advantages of the integrated contract research, development, and manufacturing organization (CRDMO) platform [1]. Profit Projections - The company projects profit for the fiscal year ending December 31, 2025, to be approximately RMB 2 billion to 2.3 billion, which marks an increase of about 237.8% to 288.5% compared to the estimated profit of approximately RMB 59.2 million for the fiscal year ending December 31, 2024 [1]. - The adjusted net profit (non-IFRS) is expected to be around RMB 2 billion to 2.3 billion, reflecting an increase of approximately 16.3% to 33.7% from the estimated adjusted net profit of about RMB 1.72 billion for the fiscal year ending December 31, 2024 [1]. Factors Influencing Profit Growth - Profit growth is primarily driven by the aforementioned revenue increase, operational management optimization leading to cost savings and efficiency improvements, and fair value gains on financial liabilities recognized for the fiscal year ending December 31, 2025 [2]. - The adjusted net profit increase is also attributed to revenue growth and operational efficiency enhancements [2].